Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Explicit consideration of baseline factors to assess recombinant tissue-type plasminogen activator response with respect to race and sex.

Mandava P, Murthy SB, Munoz M, McGuire D, Simon RP, Alexandrov AV, Albright KC, Boehme AK, Martin-Schild S, Martini S, Kent TA.

Stroke. 2013 Jun;44(6):1525-31. doi: 10.1161/STROKEAHA.113.001116. Epub 2013 May 14.

2.
3.

Influence of racial differences on outcomes after thrombolytic therapy in acute ischemic stroke.

Mishra NK, Mandava P, Chen C, Grotta J, Lees KR, Kent TA; VISTA collaboration..

Int J Stroke. 2014 Jul;9(5):613-7. doi: 10.1111/ijs.12162. Epub 2013 Oct 22.

PMID:
24148895
4.

Racial and gender differences in stroke severity, outcomes, and treatment in patients with acute ischemic stroke.

Boehme AK, Siegler JE, Mullen MT, Albright KC, Lyerly MJ, Monlezun DJ, Jones EM, Tanner R, Gonzales NR, Beasley TM, Grotta JC, Savitz SI, Martin-Schild S.

J Stroke Cerebrovasc Dis. 2014 Apr;23(4):e255-61. doi: 10.1016/j.jstrokecerebrovasdis.2013.11.003. Epub 2014 Jan 25.

5.
6.

The Effect of Age and Sex on Clinical Outcome after Intravenous Recombinant Tissue Plasminogen Activator Treatment in Patients with Acute Ischemic Stroke.

Buijs JE, Uyttenboogaart M, Brouns R, de Keyser J, Kamphuisen PW, Luijckx GJ.

J Stroke Cerebrovasc Dis. 2016 Feb;25(2):312-6. doi: 10.1016/j.jstrokecerebrovasdis.2015.09.035. Epub 2015 Oct 30.

PMID:
26527412
7.

The gender effect in stroke thrombolysis: of CASES, controls, and treatment-effect modification.

Kent DM, Buchan AM, Hill MD.

Neurology. 2008 Sep 30;71(14):1080-3. doi: 10.1212/01.wnl.0000316191.84334.bd. Epub 2008 May 21.

PMID:
18495951
8.

Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.

Brown DL, Johnston KC, Wagner DP, Haley EC Jr.

Stroke. 2004 Jan;35(1):147-50. Epub 2003 Dec 4.

9.

The response to IV rt-PA in very old stroke patients.

Gómez-Choco M, Obach V, Urra X, Amaro S, Cervera A, Vargas M, Chamorro A.

Eur J Neurol. 2008 Mar;15(3):253-6. doi: 10.1111/j.1468-1331.2007.02042.x. Epub 2008 Jan 9.

PMID:
18190509
10.

Gender differences in acute ischemic stroke: etiology, stroke patterns and response to thrombolysis.

Förster A, Gass A, Kern R, Wolf ME, Ottomeyer C, Zohsel K, Hennerici M, Szabo K.

Stroke. 2009 Jul;40(7):2428-32. doi: 10.1161/STROKEAHA.109.548750. Epub 2009 May 21.

11.

The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.

Kwiatkowski T, Libman R, Tilley BC, Lewandowski C, Grotta JC, Lyden P, Levine SR, Brott T; National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group..

Ann Emerg Med. 2005 Apr;45(4):377-84.

PMID:
15795715
12.

The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.

Kamel H, Patel N, Rao VA, Cullen SP, Faigeles BS, Smith WS, Flint AC.

J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1111-6. doi: 10.1016/j.jstrokecerebrovasdis.2012.08.017. Epub 2012 Nov 2.

PMID:
23122722
13.

Efficacy and safety assessment of alteplase in the treatment of stroke - gender differences.

Lasek-Bal A, Puz P, Kazibutowska Z.

Neurol Res. 2014 Sep;36(9):851-6. doi: 10.1179/1743132814Y.0000000331. Epub 2014 Feb 12.

PMID:
24620981
14.

Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.

Balucani C, Levine SR, Khoury JC, Khatri P, Saver JL, Broderick JP.

J Stroke Cerebrovasc Dis. 2016 Apr;25(4):894-901. doi: 10.1016/j.jstrokecerebrovasdis.2015.10.028. Epub 2016 Jan 26.

PMID:
26825352
15.

A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.

Adeoye O, Knight WA, Khoury J, Schmit PA, Sucharew H, Broderick JP, Pancioli AM; CLEAR-ER Investigators..

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):e313-5. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.012. Epub 2014 Feb 15.

16.

Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation.

Zhang JB, Ding ZY, Yang Y, Sun W, Hai F, Sui XN, Li XY, Wang HZ, Wang XT, Zheng JL.

Neurol Res. 2010 May;32(4):353-8. doi: 10.1179/016164110X12656393665206.

PMID:
20483000
17.

Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).

Rha JH, Shrivastava VP, Wang Y, Lee KE, Ahmed N, Bluhmki E, Hermansson K, Wahlgren N; SITS Investigators..

Int J Stroke. 2014 Oct;9 Suppl A100:93-101. doi: 10.1111/j.1747-4949.2012.00895.x. Epub 2012 Sep 18.

PMID:
22988894
18.

Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.

Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR; NINDS rtPA Stroke Study Group..

Stroke. 2006 Jul;37(7):1798-804. Epub 2006 Jun 8.

19.

Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.

Romano JG, Smith EE, Liang L, Gardener H, Camp S, Shuey L, Cook A, Campo-Bustillo I, Khatri P, Bhatt DL, Fonarow GC, Sacco RL, Schwamm LH.

JAMA Neurol. 2015 Apr;72(4):423-31. doi: 10.1001/jamaneurol.2014.4354.

PMID:
25642650
20.

Racial and ethnic disparities in the use of intravenous recombinant tissue plasminogen activator and outcomes for acute ischemic stroke.

Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA.

J Stroke Cerebrovasc Dis. 2013 Feb;22(2):154-60. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.003. Epub 2011 Dec 11.

PMID:
22155116

Supplemental Content

Support Center